NSE · NATCAPSUQ · Pharmaceuticals
Natural Capsules Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹47 Cr with net profit ₹5 Cr — a 10.28% net margin, versus 9.39% the period before.
Shareholding
As of 2026-09-30
- Promoter50.92%
- Public49%
- FII0.08%
8,724 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.78× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #68 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,51,075 Cr | 36.65 | 5.05 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,30,972 Cr | 97.74 | 21.57 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,18,693 Cr | 26.12 | 4.27 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,15,267 Cr | 41.17 | 2.96 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,12,442 Cr | 36.21 | 3.18 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,09,044 Cr | 46.73 | 6.23 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,04,903 Cr | 25.85 | 2.67 | 10.13% | 10.88% |
| Lupin Limited | ₹90,558 Cr | 16.07 | 3.76 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹74,507 Cr | 36.78 | 6.65 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹61,146 Cr | 28.2 | 4.11 | 13.91% | 13.23% |
| Natural Capsules Limited(this company) | ₹158 Cr | — | 0.93 | -5.65% | -6.28% |
AI analysis
AI-generated · google/gemini-2.5-flashNatural Capsules Limited is listed on the Indian markets with a market capitalization of Rs 146 Cr. The company reported a revenue of Rs 169.91 Cr, experiencing a revenue growth of 8.9%. Its profit margin is -11.19%, resulting in an EPS of 0. The stock's 52-week high is Rs 296 and its 52-week low is Rs 136.36.
Positives
- +Promoter shareholding is 50.92% as of June 30, 2026.
- +Promoter pledge is 0%, indicating no shares are pledged.
Negatives
- −The profit margin is negative at -11.19%.
- −Return on Equity (ROE) is negative at -7.27%.
- −Return on Capital Employed (ROCE) is negative at -4.85%.
- −The company recorded a net loss of Rs -3.45 Cr in March 2026.
- −EPS is 0, indicating no earnings per share.
Financial performance
Natural Capsules Limited reported a total revenue of Rs 169.91 Cr, which represents an 8.9% growth. The company's profit margin stands at -11.19%. Quarterly revenue in March 2026 was Rs 58.45 Cr, with a net loss of Rs -3.45 Cr. This follows a trend of negative net profit in the preceding quarters, including -4.93 Cr in December 2025 and -6.99 Cr in September 2025.
Profitability & returns
The company's profitability metrics indicate negative returns, with a Return on Equity (ROE) of -7.27% and a Return on Capital Employed (ROCE) of -4.8462%. The profit margin is -11.19% for the latest fiscal year. The Earnings Per Share (EPS) is 0.
Balance sheet
Natural Capsules Limited has a book value of Rs 212.91. The debt-to-equity ratio is 0.49, indicating some debt in relation to its equity. No further details on assets or liabilities are available in the provided data.
Ownership & pledges
Public shareholding is 49.0811%. There is no promoter pledge reported (0%).
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.